Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Healthcare Medical Devices
Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Diagnos Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(22)
•••
Post by modulexon Jan 18, 2023 3:58pm
289 Views
Post# 35231532

LET'S ALL BE REWARDED

LET'S ALL BE REWARDED
To:
squenneville@echelonpartners.com

January 18, 2023
 
Good day Mr. Quenneville,
 
I am somewhat pleased that you are instilling hope in DIAGNOS, believing it is poised to win a Quebec government RFP (Request for Proposal) contract, perhaps to be shared with RETINA LABS?
 
I will however never buy again (TSXV:ADK) shares as this public company has been sheerly unable to create shareholders value for so many years.
 
I am patiently keeping my 4,000 shares purchased 7 years ago for a definite sell-off above $1.
 
Best to you in your career endeavours,
 
---
 
2023
 

Rating: Speculative Buy

Target Price: $1.00

Projected Return: 257 per cent

Analyst Stefan Quenneville chose healthcare AI platform Diagnos as a Top Pick, saying its partnership with Retinal Labs appears poised to win a Quebec government RFP for an AI-based teleophthalmology platform to screen diabetics province-wide for diabetic retinopathy, a potential catalyst for the stock.

 

 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities